{"title":"Dupilumab用于标准三联疗法难治性嗜酸性食管炎。","authors":"Rémi Gason, Jean-Baptiste Zeevaert, Floriane Ausloos, Fernand Weerts","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>We report the case of a young man presenting with dysphagia and frequent food impactions, which led to the diagnosis of eosinophilic esophagitis based on endoscopic examination and confirmed anatomopathologically. Despite a triple therapy regimen including a high-dose proton pump inhibitor, an elimination of allergenic foods based on prick tests, and oral budesonide, there was no significant and sustained clinical or endoscopic improvement. In this context, through a compassionate use program, we initiated biotherapy with dupilumab, a monoclonal antibody targeting interleukin 4 and interleukin 13 receptors, which was recently approved for the treatment of refractory eosinophilic esophagitis by the European Medicines Agency. We report our experience over 6 months with this innovative treatment, which has been reimbursed in Belgium under certain conditions since November 1st, 2024.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 7-8","pages":"491-495"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Dupilumab for eosinophilic esophagitis refractory to standard triple therapy].\",\"authors\":\"Rémi Gason, Jean-Baptiste Zeevaert, Floriane Ausloos, Fernand Weerts\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We report the case of a young man presenting with dysphagia and frequent food impactions, which led to the diagnosis of eosinophilic esophagitis based on endoscopic examination and confirmed anatomopathologically. Despite a triple therapy regimen including a high-dose proton pump inhibitor, an elimination of allergenic foods based on prick tests, and oral budesonide, there was no significant and sustained clinical or endoscopic improvement. In this context, through a compassionate use program, we initiated biotherapy with dupilumab, a monoclonal antibody targeting interleukin 4 and interleukin 13 receptors, which was recently approved for the treatment of refractory eosinophilic esophagitis by the European Medicines Agency. We report our experience over 6 months with this innovative treatment, which has been reimbursed in Belgium under certain conditions since November 1st, 2024.</p>\",\"PeriodicalId\":94201,\"journal\":{\"name\":\"Revue medicale de Liege\",\"volume\":\"80 7-8\",\"pages\":\"491-495\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revue medicale de Liege\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue medicale de Liege","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[Dupilumab for eosinophilic esophagitis refractory to standard triple therapy].
We report the case of a young man presenting with dysphagia and frequent food impactions, which led to the diagnosis of eosinophilic esophagitis based on endoscopic examination and confirmed anatomopathologically. Despite a triple therapy regimen including a high-dose proton pump inhibitor, an elimination of allergenic foods based on prick tests, and oral budesonide, there was no significant and sustained clinical or endoscopic improvement. In this context, through a compassionate use program, we initiated biotherapy with dupilumab, a monoclonal antibody targeting interleukin 4 and interleukin 13 receptors, which was recently approved for the treatment of refractory eosinophilic esophagitis by the European Medicines Agency. We report our experience over 6 months with this innovative treatment, which has been reimbursed in Belgium under certain conditions since November 1st, 2024.